# US 2006/0039979 A1 · Drug delivery system using subconjunctival depot

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0039979 A1
- Document ID: US20060039979A1
- Status: Published application
- Kind: A1
- Application number: 10/537,453
- Filed: 2003-12-03
- Published: 2006-02-23
- Earliest claimed: 2002-12-04
- Inventors: Kazuhito Yamada; Mitsuaki Kuwano
- Web page: https://patentgrep.com/patent/US20060039979A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/02: for peripheral neuropathies
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a drug delivery system to a posterior segment wherein a pharmaceutical composition comprising a drug and a vehicle is administered subconjunctivally to form a depot out of the vehicle, and thereby the drug is gradually released from the depot to enable an effective concentration of the drug to be maintained, the pharmaceutical composition comprising the vehicle which is in the form of gel subconjunctivally and the drug suspended in the vehicle.

## Claims

### Claim 1

A drug delivery system to a posterior segment wherein a pharmaceutical composition comprising a drug and a vehicle is administered subconjunctivally to form a depot out of the vehicle, and thereby the drug is gradually released from the depot to enable an effective concentration of the drug to be maintained, the pharmaceutical composition comprising the vehicle which is in the form of gel subconjunctivally and the drug suspended in the vehicle.

### Claim 2 (depends on 1)

The drug delivery system as claimed in claim 1, wherein a dosage form of the pharmaceutical composition is an injection.

### Claim 3 (depends on 1)

The drug delivery system as claimed in claim 1, wherein the vehicle is in the form of gel on administration or a vehicle which is in the form of solution on administration and in the form of a gel subconjunctivally after administration.

### Claim 4 (depends on 3)

The drug delivery system as claimed in claim 3, wherein the vehicle is a thermosensitive gel, an ion-sensitive gel or a pH-sensitive gel.

### Claim 5 (depends on 1, 2, 3, 4)

The drug delivery system as claimed in any one of claims 1 to 4, wherein the drug is a hardly water-soluble drug.

### Claim 6 (depends on 5)

The drug delivery system as claimed in claim 5, wherein the hardly water-soluble drug is a drug which has lipid-solubility by which the drug is not soluble in the vehicle and can be suspended in the vehicle.

### Claim 7 (depends on 5)

The drug delivery system as claimed in claim 5, wherein the hardly water-soluble drug is a drug which is made hardly water-soluble by converting a water-soluble drug into its prodrug.

### Claim 8 (depends on 1, 2, 3, 4)

The drug delivery system as claimed in any one of claims 1 to 4, wherein the drug is a water-soluble drug, the drug is encapsulated in a nanosphere or a microsphere, then it is suspended in a vehicle which is in the form of gel subconjunctivally to give a pharmaceutical composition, and the composition is administered subconjunctivally.

### Claim 9

A subconjunctival injection comprising a drug suspended in a vehicle which is in the form of gel subconjunctivally, wherein the vehicle of the injection forms a depot subconjunctivally, and the drug is released gradually from the depot, thereby enabling a drug concentration in a posterior segment tissue to be maintained.

### Claim 10 (depends on 1)

The drug delivery system as claimed in claim 1, wherein the posterior segment is a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

### Claim 11 (depends on 1)

The drug delivery system as claimed in claim 1, wherein the drug is a drug for treatment or prevention of a disease of a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

### Claim 12 (depends on 1)

The drug delivery system as claimed in claim 1, wherein the drug is an anti-inflammatory, an immunosuppressor, an antiviral, an anticancer drug, an angiogenesis inhibitor, an optic neural protectant, an antimicrovial or an antifungal agent.

### Claim 13 (depends on 9)

The subconjunctival injection as claimed in claim 9, wherein the posterior segment is a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

### Claim 14 (depends on 9)

The subconjunctival injection as claimed in claim 9, wherein the drug is a drug for treatment or prevention of a disease of a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

### Claim 15 (depends on 9)

The subconjunctival injection as claimed in claim 9, wherein the drug is an anti-inflammatory, an immunosuppressor, an antiviral, an anticancer drug, an angiogenesis inhibitor, an optic neural protectant, an antimicrovial or an antifungal agent.
